Pseudomonas aeruginosa
General medical information for education only, not medical advice. Treatment considerations summarize published guidance at drug-class level; therapy is chosen by the treating clinician using susceptibility results, local resistance patterns and current guidelines.
Overview
A non-fermenting Gram-negative rod thriving in moist environments; a major healthcare-associated pathogen.
Infections
Catheter-associated and complicated urinary tract infection, pneumonia, wound and burn infection, otitis externa, keratitis, bloodstream infection.
Signs and symptoms
Wound and burn infection: green-blue drainage with a sweet, grape-like odor and spreading redness. Pneumonia in ventilated patients or people with cystic fibrosis: fever, thick purulent secretions and worsening breathing. Urinary infection in catheterized patients: fever and flank or suprapubic pain. Outer-ear infection (swimmer's ear): ear pain, itching and discharge. Eye infection in contact-lens wearers: a painful red eye.
Antibiotic and antimicrobial resistance
Intrinsically resistant to many antibiotics; acquires further resistance through efflux, porin loss, AmpC overproduction (AmpC) and carbapenemases such as VIM (carbapenemases).
Treatment considerations
Anti-pseudomonal agents (for example piperacillin-tazobactam, cefepime, ceftazidime, carbapenems, ciprofloxacin) guided by susceptibility testing; oral options are limited.
Infection control and public health
Multidrug-resistant strains need contact precautions.

Sources
- CDC. Pseudomonas aeruginosa.
- IDSA. Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.
- CDC. Healthcare-associated infections: diseases and organisms.
Sources accessed November 2026. Links open external sites that InnovexLab does not control.
Medical disclaimer
This page is general educational information summarized from published public-health and professional-society guidance. It is not medical advice, a diagnosis or a treatment recommendation, and reading it does not create a clinician–patient relationship with InnovexLab. Decisions about testing, diagnosis and treatment belong to the treating clinician, using the patient’s history and examination, laboratory and susceptibility results, local resistance patterns and current guidelines. Guidance changes over time; consult the original sources for the latest version. InnovexLab provides this information as is and does not warrant that it is complete or current.
Patients with questions about their health should contact their own healthcare provider. In an emergency, call 911.